Paper28314920
[New antibiotics - standstill or progress].
Rademacher J and 1 other. Med Klin Intensivmed Notfmed, 2017. Cited by 5 papers, by iCite.
Cite this record
ConductScience Library. [New antibiotics - standstill or progress]. Papers, record 28314920. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28314920
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics22
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Anti-Bacterial Agents | Major topic |
| Bacterial Infections | Major topic |
| Drug Approval | Major topic |
| Drug Resistance, Multiple, Bacterial | Major topic |
| Azabicyclo Compounds | |
| Ceftazidime | |
| Cephalosporins | |
| Clinical Trials as Topic | |
| Drug Combinations | |
| Ephedrine | |
| Humans | |
| Macrolides | |
| Methicillin-Resistant Staphylococcus aureus | |
| Organophosphates | |
| Oxazoles | |
| Penicillanic Acid | |
| Phenobarbital | |
| Staphylococcal Infections | |
| Tazobactam | |
| Theophylline | |
| Triazoles | |
| Ceftaroline |
Source PubMed
References15
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 22247123 | Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. | Clin Infect Dis | 2012 | https://conductscience.org/library/papers/22247123 | PubMed |
| 2 | 25931244 | Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). | Lancet | 2015 | https://conductscience.org/library/papers/25931244 | PubMed |
| 3 | 24580739 | European perspective and update on the management of nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolid. | Clin Microbiol Infect | 2014 | https://conductscience.org/library/papers/24580739 | PubMed |
| 4 | 19085949 | Telithromycin-associated hepatotoxicity: Clinical spectrum and causality assessment of 42 cases. | Hepatology | 2009 | https://conductscience.org/library/papers/19085949 | PubMed |
| 5 | 27107460 | Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. | Lancet Infect Dis | 2016 | https://conductscience.org/library/papers/27107460 | PubMed |
| 6 | 24909499 | Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. | Lancet Infect Dis | 2014 | https://conductscience.org/library/papers/24909499 | PubMed |
| 7 | 23391714 | Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial. | J Antimicrob Chemother | 2013 | https://conductscience.org/library/papers/23391714 | PubMed |
| 8 | 23507282 | Randomized, double-blind, multicenter phase 2 study comparing the efficacy and safety of oral solithromycin (CEM-101) to those of oral levofloxacin in the treatment of patients with community-acquired bacterial pneumonia. | Antimicrob Agents Chemother | 2013 | https://conductscience.org/library/papers/23507282 | PubMed |
| 9 | 25539586 | Ceftaroline fosamil versus ceftriaxone for the treatment of Asian patients with community-acquired pneumonia: a randomised, controlled, double-blind, phase 3, non-inferiority with nested superiority trial. | Lancet Infect Dis | 2015 | https://conductscience.org/library/papers/25539586 | PubMed |
| 10 | 26962078 | Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program. | Clin Infect Dis | 2016 | https://conductscience.org/library/papers/26962078 | PubMed |
| 11 | 23403680 | Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. | JAMA | 2013 | https://conductscience.org/library/papers/23403680 | PubMed |
| 12 | 24723282 | A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia. | Clin Infect Dis | 2014 | https://conductscience.org/library/papers/24723282 | PubMed |
| 13 | 25670823 | Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI). | Clin Infect Dis | 2015 | https://conductscience.org/library/papers/25670823 | PubMed |
| 14 | 23145859 | Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study. | Curr Med Res Opin | 2012 | https://conductscience.org/library/papers/23145859 | PubMed |
| 15 | 24615816 | Dramatic increase in vancomycin-resistant enterococci in Germany. | J Antimicrob Chemother | 2014 | https://conductscience.org/library/papers/24615816 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 35982884 | Acquaintance and Awareness of Budding Physicians toward Antimicrobials' Use: Need of the Hour. | J Lab Physicians | 2022 | https://conductscience.org/library/papers/35982884 | PubMed |
| 31546812 | Antibiotic Use: A Cross-Sectional Study Evaluating the Understanding, Usage and Perspectives of Medical Students and Pathfinders of a Public Defence University in Malaysia. | Antibiotics (Basel) | 2019 | https://conductscience.org/library/papers/31546812 | PubMed |
| 28613234 | Synthesis and Bioactivity Evaluation of N-Arylsulfonylindole Analogs Bearing a Rhodanine Moiety as Antibacterial Agents. | Molecules | 2017 | https://conductscience.org/library/papers/28613234 | PubMed |
| 28593351 | [What is the perception of the 10-point plan of the German Federal Ministry of Health against multidrug-resistant pathogens and measures of antibiotic stewardship? : An interdisciplinary analysis among German clinicians and development of a decision tool for urologists]. | Urologe A | 2017 | https://conductscience.org/library/papers/28593351 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/28314920
GET https://conductscience.org/api/papers/v1/28314920/authors